相关实验视频

Updated: Jul 12, 2025

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

An Automated Radiosynthesis of [⁶⁸Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

纤维细胞激活蛋白抑制剂-PET/CT:临床和药理方面的最新话题

Yuji Nakamoto¹, Shingo Baba², Hayato Kaida³

¹Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. ynakamo1@kuhp.kyoto-u.ac.jp.

Annals of nuclear medicine

|October 20, 2023

概括

带有纤维细胞激活蛋白抑制剂 (FAPI) 的正子发射断层扫描 (PET) 提供了先进的瘤成像,与18F-氧葡萄糖 (FDG) PET精度相匹配或超过. FAPI PET还显示出诊断非癌症疾病的潜力.

科学领域:

核医学就是核医学.
瘤成像学成像学
放射性药物开发放射性药物开发

背景情况:

定子发射断层扫描 (PET) 是瘤学中一个关键的成像模式.
纤维细胞激活蛋白 (FAP) 越来越被认为是癌症成像的目标.
当前像18F-氧葡萄糖 (FDG) 这样的成像剂在某些瘤类型和非新发性疾病中存在局限性.

研究的目的:

为提供纤维细胞激活蛋白抑制剂 (FAPI) PET成像的全面概述.
讨论FAPI PET的临床实用性,特别是在瘤诊断方面.
探索FAPI PET在非新发性疾病中的新兴应用.

主要方法:

对最近发表的关于FAPI PET成像的文献的综述.
与现有的PET标记剂相比,诊断准确性的分析.
检查各种放射性标记的FAPI化合物 (例如标记18F和68Ga).

主要成果:

在描绘大多数恶性瘤方面,FAPI PET具有很高的准确性,与FDG PET相比或更高.
在FDG PET上,FAPI PET可以识别错过的或不确定的病变.
新出现的证据表明,FAPI PET在非新形成性疾病 (如呼吸道和心脏病) 中具有实用性.

结论:

FAPI PET是一种有前途的高级成像工具,用于瘤诊断.
在特定的临床场景中,FAPI PET比FDG PET具有优势.
对FAPI PET合成和治疗应用的进一步研究是有必要的.

关键词:

FAPIAPI FAPIAPI 这是一个很好的方法.德国联邦航空公司 (FDG)图像成像是一种成像.恶性瘤是一种恶性瘤.这是新质体新质体.在这里,PET是PET.

更多相关视频

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT

Published on: May 2, 2012

Functional Imaging of Brown Fat in Mice with 18F-FDG micro-PET/CT

Functional Imaging of Brown Fat in Mice with 18F-FDG micro-PET/CT

Published on: November 23, 2012

相关概念视频

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...